Cas:1159511-75-7 7-bromo-3-methyl-2H-indazole manufacturer & supplier

We serve Chemical Name:7-bromo-3-methyl-2H-indazole CAS:1159511-75-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

7-bromo-3-methyl-2H-indazole

Chemical Name:7-bromo-3-methyl-2H-indazole
CAS.NO:1159511-75-7
Synonyms:7-Bromo-3-methyl-1H-indazole;CL3496;INDAZOLE,7-BROMO-3-METHYL
Molecular Formula:C8H7BrN2
Molecular Weight:211.05900
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:28.68000
Exact Mass:209.97900
LogP:2.63380

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 7-Bromo-3-methyl-1H-indazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,INDAZOLE,7-BROMO-3-METHYL physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-Bromo-3-methyl-1H-indazole Use and application,CL3496 technical grade,usp/ep/jp grade.


Related News: For example, there are concerns that PFAS’ effect on the thyroid could lead to thyroid cancer, van Gerwen said. 7-bromo-3-methyl-2H-indazole manufacturer The main API products include antihypertensive, psychotropic and anti-AIDS special APIs. Antihypertensive APIs are mainly pulic and sartan drugs, and they are the world’s major suppliers of pulic and sartan APIs. 7-bromo-3-methyl-2H-indazole supplier The main API products include antihypertensive, psychotropic and anti-AIDS special APIs. Antihypertensive APIs are mainly pulic and sartan drugs, and they are the world’s major suppliers of pulic and sartan APIs. 7-bromo-3-methyl-2H-indazole vendor For example, there are concerns that PFAS’ effect on the thyroid could lead to thyroid cancer, van Gerwen said. 7-bromo-3-methyl-2H-indazole factory Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged.